RESEARCH AND DEVELOPMENT AT ALK

Pioneering allergy research

Understanding allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.

understanding_allergy

News

  • Post date
    02/14/2017
    Annual General Meeting in ALK-Abelló A/S on 15 March 2017
  • Post date
    02/07/2017
    ALK releases its annual report 2016
  • Post date
    01/10/2017
    Carsten Hellmann joins ALK as new President and CEO
  • Post date
    01/04/2017
    ALK upgrades its full-year 2016 financial outlook following better than expected Q4 sales
  • Post date
    12/22/2016
    ALK strengthens its US presence through acquisition
  • Post date
    12/14/2016
    ALK – Financial calendar for the 2017 financial year
  • Post date
    12/02/2016
    Notification of ownership in ALK
  • Post date
    11/10/2016
    Nine-month interim report (Q3) 2016
  • Post date
    11/02/2016
    Release date of nine-month interim report (Q3) 2016 for ALK
Prevention of asthma symptoms
ALK is leading the industry’s research into the role respiratory allergies play in asthma. As part of this research, we conducted the world’s largest allergy immunotherapy trial ever carried out in children to investigate the effect of a new treatment on the risk of developing asthma.
The link between allergic rhinitis and allergic asthma
Respiratory allergens, such as house dust mites, can cause the airways to inflame. In time, this can lead to asthma, or the worsening of symptoms in people who are already asthmatic. A new treatment option can treat both house dust mite allergic rhinitis and allergic asthma.

ALK in brief

ALK at a glance
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
Global presence
ALK employs around 2,000 employees worldwide and has affiliates, production facilities and distributors around the globe. Today, around 1.5 million people worldwide use our products.
ALK's pipeline
Our development programme covers the four most important outdoor allergens in Europe, the USA and Japan (grass, birch and related trees, ragweed and Japanese cedar) and the most important indoor allergen in the world (house dust mites).
ALK's history
ALK has been at the forefront of allergy treatment for almost a century. Our story can be traced back to a small laboratory in Copenhagen, Denmark, in 1923.